Literature DB >> 20666983

Decreased ratio of CD8+ T cells to regulatory T cells associated with decreased survival in dogs with osteosarcoma.

B J Biller1, A Guth, J H Burton, S W Dow.   

Abstract

BACKGROUND: Increased numbers of regulatory T cells (Treg) and decreased ratios of CD8+ T cells to Treg have been shown to correlate with decreased survival times (ST) in humans with certain malignancies. A possible connection between Treg and ST in dogs with cancer has not been investigated previously. HYPOTHESIS: The purpose of this study was to compare numbers of Treg and T lymphocyte subsets in dogs with osteosarcoma (OSA) to those of healthy dogs and to determine whether pretreatment values were associated with disease-free interval or with ST. We hypothesized that Treg numbers would be increased in dogs with cancer and that dogs with a high percentage of Treg would have a poorer prognosis. ANIMALS: Twelve client-owned dogs with appendicular OSA were entered into a prospective clinical trial. Twenty-two healthy dogs were used as controls.
METHODS: The percentages and numbers of Treg and CD4+ and CD8+ T cells in blood, lymph nodes, and tumors were determined with flow cytometry and compared between dogs with OSA and control dogs.
RESULTS: Dogs with OSA had significantly fewer circulating CD8+ T cells and significantly more Treg compared with healthy dogs. The CD8/Treg ratio also was significantly lower in dogs with OSA compared with control dogs. In dogs with OSA, a decreased CD8/Treg ratio was associated with significantly shorter STs.
CONCLUSIONS: These data support a role for Treg in the immune control of canine OSA and suggest that determination of the CD8/Treg ratio may be useful for assessing outcomes.
Copyright © 2010 by the American College of Veterinary Internal Medicine.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20666983      PMCID: PMC3557512          DOI: 10.1111/j.1939-1676.2010.0557.x

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  32 in total

1.  Lymphocyte subsets in peripheral blood of dogs--a flow cytometric study.

Authors:  M Faldyna; L Levá; P Knötigová; M Toman
Journal:  Vet Immunol Immunopathol       Date:  2001-09-28       Impact factor: 2.046

Review 2.  A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3.

Authors:  Jason D Fontenot; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2005-04       Impact factor: 25.606

Review 3.  Regulatory cells and human cancer.

Authors:  Clare Baecher-Allan; David E Anderson
Journal:  Semin Cancer Biol       Date:  2005-12-27       Impact factor: 15.707

4.  Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.

Authors:  Jens Dannull; Zhen Su; David Rizzieri; Benjamin K Yang; Doris Coleman; Donna Yancey; Aijing Zhang; Philipp Dahm; Nelson Chao; Eli Gilboa; Johannes Vieweg
Journal:  J Clin Invest       Date:  2005-11-23       Impact factor: 14.808

5.  Differences in immune cells engaged in cell-mediated immunity after chemotherapy for far advanced pancreatic cancer.

Authors:  Seungmin Bang; Han-Soo Kim; Yee Shin Choo; Seung Woo Park; Jae Bock Chung; Si Young Song
Journal:  Pancreas       Date:  2006-01       Impact factor: 3.327

6.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.

Authors:  Eiichi Sato; Sara H Olson; Jiyoung Ahn; Brian Bundy; Hiroyoshi Nishikawa; Feng Qian; Achim A Jungbluth; Denise Frosina; Sacha Gnjatic; Christine Ambrosone; James Kepner; Tosin Odunsi; Gerd Ritter; Shashikant Lele; Yao-Tseng Chen; Haruo Ohtani; Lloyd J Old; Kunle Odunsi
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-12       Impact factor: 11.205

7.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

8.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Authors:  Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2004-08-22       Impact factor: 53.440

9.  Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells.

Authors:  Manuelle Viguier; Fabrice Lemaître; Olivier Verola; Min-Sun Cho; Guy Gorochov; Louis Dubertret; Hervé Bachelez; Philippe Kourilsky; Laurent Ferradini
Journal:  J Immunol       Date:  2004-07-15       Impact factor: 5.422

10.  Feline immunodeficiency virus infection phenotypically and functionally activates immunosuppressive CD4+CD25+ T regulatory cells.

Authors:  Thomas W Vahlenkamp; Mary B Tompkins; Wayne A F Tompkins
Journal:  J Immunol       Date:  2004-04-15       Impact factor: 5.422

View more
  25 in total

Review 1.  Genetically modified T-cell therapy for osteosarcoma.

Authors:  Christopher DeRenzo; Stephen Gottschalk
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

2.  Suppression of canine myeloid cells by soluble factors from cultured canine tumor cells.

Authors:  J Wasserman; L Diese; Z VanGundy; C London; W E Carson; T L Papenfuss
Journal:  Vet Immunol Immunopathol       Date:  2011-12-28       Impact factor: 2.046

3.  Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms.

Authors:  Mikayel Mkrtichyan; Yana G Najjar; Estella C Raulfs; Maher Y Abdalla; Raed Samara; Rinat Rotem-Yehudar; Larry Cook; Samir N Khleif
Journal:  Eur J Immunol       Date:  2011-08-17       Impact factor: 5.532

4.  Association of macrophage and lymphocyte infiltration with outcome in canine osteosarcoma.

Authors:  Sita S Withers; Katherine A Skorupski; Daniel York; Jin W Choi; Kevin D Woolard; Renee Laufer-Amorim; Ellen E Sparger; Carlos O Rodriguez; Stephen J McSorley; Arta M Monjazeb; William J Murphy; Robert J Canter; Robert B Rebhun
Journal:  Vet Comp Oncol       Date:  2018-09-19       Impact factor: 2.613

5.  Immune response to RB1-regulated senescence limits radiation-induced osteosarcoma formation.

Authors:  Maya Kansara; Huei San Leong; Dan Mei Lin; Sophie Popkiss; Puiyi Pang; Dale W Garsed; Carl R Walkley; Carleen Cullinane; Jason Ellul; Nicole M Haynes; Rod Hicks; Marieke L Kuijjer; Anne-Marie Cleton-Jansen; Philip W Hinds; Mark J Smyth; David M Thomas
Journal:  J Clin Invest       Date:  2013-11-15       Impact factor: 14.808

Review 6.  Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies.

Authors:  Ingrid Lilienthal; Nikolas Herold
Journal:  Int J Mol Sci       Date:  2020-09-19       Impact factor: 5.923

7.  Metastatic immune infiltrates correlate with those of the primary tumour in canine osteosarcoma.

Authors:  Sita S Withers; Daniel York; Jin W Choi; Kevin D Woolard; Renee Laufer-Amorim; Ellen E Sparger; Jenna H Burton; Stephen J McSorley; Arta M Monjazeb; William J Murphy; Robert J Canter; Robert B Rebhun
Journal:  Vet Comp Oncol       Date:  2019-04-08       Impact factor: 2.613

Review 8.  Genetically Modified T-Cell Therapy for Osteosarcoma: Into the Roaring 2020s.

Authors:  Christopher DeRenzo; Stephen Gottschalk
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 9.  Prognostic factors in canine appendicular osteosarcoma - a meta-analysis.

Authors:  Ilse Boerman; Gayathri T Selvarajah; Mirjam Nielen; Jolle Kirpensteijn
Journal:  BMC Vet Res       Date:  2012-05-15       Impact factor: 2.741

10.  Comparative analysis of genome-wide DNA methylation identifies patterns that associate with conserved transcriptional programs in osteosarcoma.

Authors:  Lauren J Mills; Milcah C Scott; Pankti Shah; Anne R Cunanan; Archana Deshpande; Benjamin Auch; Bridget Curtin; Kenneth B Beckman; Logan G Spector; Aaron L Sarver; Subbaya Subramanian; Todd A Richmond; Jaime F Modiano
Journal:  Bone       Date:  2020-10-27       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.